MXPA02008097A - Formulacion de propol con inhibicion microbiana mejorada. - Google Patents

Formulacion de propol con inhibicion microbiana mejorada.

Info

Publication number
MXPA02008097A
MXPA02008097A MXPA02008097A MXPA02008097A MXPA02008097A MX PA02008097 A MXPA02008097 A MX PA02008097A MX PA02008097 A MXPA02008097 A MX PA02008097A MX PA02008097 A MXPA02008097 A MX PA02008097A MX PA02008097 A MXPA02008097 A MX PA02008097A
Authority
MX
Mexico
Prior art keywords
formulation
fat
microbial inhibition
enhanced microbial
propofol formulation
Prior art date
Application number
MXPA02008097A
Other languages
English (en)
Inventor
Jie Fei Din
Original Assignee
Amphastar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amphastar Pharmaceuticals Inc filed Critical Amphastar Pharmaceuticals Inc
Publication of MXPA02008097A publication Critical patent/MXPA02008097A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan formulaciones farmaceuticas estables y esteriles de emulsiones de aceite en agua de Propofol que no contienen conservadores, las cuales contienen cantidades optimas de lecitina de huevo y aceite de soya, con un intervalo de pH adecuado para evitar el crecimiento significativo de microorganismos durante por lo menos 24 horas despues de la contaminacion extrinseca fortuita. El pH menor en la formulacion ha demostrado que tiene la mayor actividad antimicrobiana. La cantidad reducida de grasa en la formulacion tambien permite la sedacion cronica durante periodos de tiempo prolongados con una disminucion en la probabilidad de sobrecarga de grasa en la sangre.
MXPA02008097A 2000-12-20 2001-07-16 Formulacion de propol con inhibicion microbiana mejorada. MXPA02008097A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/745,018 US6399087B1 (en) 2000-12-20 2000-12-20 Propofol formulation with enhanced microbial inhibition
PCT/US2001/022248 WO2002049631A1 (en) 2000-12-20 2001-07-16 Propofol formulation with enhanced microbial inhibition

Publications (1)

Publication Number Publication Date
MXPA02008097A true MXPA02008097A (es) 2004-09-10

Family

ID=24994883

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02008097A MXPA02008097A (es) 2000-12-20 2001-07-16 Formulacion de propol con inhibicion microbiana mejorada.

Country Status (11)

Country Link
US (1) US6399087B1 (es)
EP (1) EP1250130A4 (es)
JP (1) JP2004516265A (es)
CN (1) CN1359677A (es)
AU (1) AU7592501A (es)
BR (1) BR0109769A (es)
CA (1) CA2397990A1 (es)
MX (1) MXPA02008097A (es)
RU (1) RU2244545C2 (es)
UA (1) UA73970C2 (es)
WO (1) WO2002049631A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20040171691A1 (en) * 2002-10-29 2004-09-02 Transform Pharmaceuticals, Inc. Propofol with cysteine
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US7468394B1 (en) * 2003-03-11 2008-12-23 Amphastar Pharmaceuticals, Inc. Sterile pharmaceutical composition and process for a solution of propofol emulsion having microbial growth retardation
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) * 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US8546453B2 (en) * 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
RU2451510C2 (ru) * 2005-08-31 2012-05-27 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Композиции и способы получения слаборастворимых в воде лекарственных средств с увеличенной стабильностью
BRPI0615292A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
CN101411685B (zh) * 2007-10-19 2011-04-20 上海医药工业研究院 一种静脉麻醉药2,6-二异丙基苯酚微乳组合物及其制备方法
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
JP6073244B2 (ja) * 2011-01-04 2017-02-01 ノバリック ゲーエムベーハー 部分フッ素化アルカンを含むｏ／ｗエマルション
JP2019142972A (ja) * 2011-03-04 2019-08-29 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
CN107088226A (zh) * 2011-03-04 2017-08-25 格吕伦塔尔有限公司 他喷他多的胃肠外给药
EP2680832B1 (en) 2011-03-04 2019-09-04 Grünenthal GmbH Aqueous pharmaceutical formulation of tapentadol for oral administration
EP2680834B1 (en) 2011-03-04 2017-10-18 Grünenthal GmbH Semisolid aqueous pharmaceutical composition containing tapentadol
AU2012260787B2 (en) 2011-05-25 2017-02-02 Dermaliq Therapeutics, Inc. Topical pharmaceutical composition based on semifluorinated alkanes
JP2013001700A (ja) * 2011-06-21 2013-01-07 Fujifilm Corp プロポフォール含有水中油型エマルション組成物
JP5759804B2 (ja) * 2011-06-27 2015-08-05 富士フイルム株式会社 容器詰製剤
EP2806886B1 (en) 2012-01-23 2017-03-01 Novaliq GmbH Stabilised protein compositions based on semifluorinated alkanes
AU2013263292B2 (en) 2012-05-16 2018-03-08 Maninder SANDHU Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
CA2883002C (en) 2012-09-12 2019-05-21 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
CN104755073B (zh) 2012-09-12 2017-12-26 诺瓦利克有限责任公司 半氟化烷烃组合物
CN105555311B (zh) 2013-07-23 2021-10-08 诺瓦利克有限责任公司 稳定的抗体组合物
MX2017012312A (es) 2015-03-27 2018-01-18 Gruenenthal Gmbh Formulacion estable para administracion parenteral de tapentadol.
EP3331567B1 (en) * 2015-07-24 2020-09-23 Neon Laboratories Ltd. Stabilized injectable emulsion of propofol and ketamine
US11622937B2 (en) 2015-08-20 2023-04-11 Mewa Singh Polyphenolic polymer to make water-insoluble molecules become water-soluble
JP6642935B2 (ja) 2015-09-30 2020-02-12 ノバリック ゲーエムベーハー 眼投与用の半フッ素化化合物
DE202016008738U1 (de) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorierte Verbindungen und ihre Zusammensetzungen
PL3442480T3 (pl) 2016-06-23 2020-04-30 Novaliq Gmbh Sposób podawania miejscowego
CN109890374A (zh) 2016-09-22 2019-06-14 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
AU2017329983B2 (en) 2016-09-23 2022-05-05 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
KR20190057349A (ko) 2016-09-23 2019-05-28 그뤼넨탈 게엠베하 타펜타돌의 비경구 투여용 안정한 제제
BR112019021917A8 (pt) 2017-04-21 2023-03-21 Novaliq Gmbh Composições de iodo
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
BR112020006072A2 (pt) 2017-09-27 2020-10-06 Novaliq Gmbh composições oftalmáticas compreendendo latanoprost para uso no tratamento de doenças oculares
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
WO2020074697A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1105096T3 (da) * 1998-08-19 2004-03-08 Skyepharma Canada Inc Injicerbare vandige propofoldispersioner
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics

Also Published As

Publication number Publication date
EP1250130A1 (en) 2002-10-23
EP1250130A4 (en) 2006-03-15
US6399087B1 (en) 2002-06-04
JP2004516265A (ja) 2004-06-03
UA73970C2 (en) 2005-10-17
RU2244545C2 (ru) 2005-01-20
BR0109769A (pt) 2003-02-04
RU2002122394A (ru) 2004-03-20
WO2002049631A1 (en) 2002-06-27
CN1359677A (zh) 2002-07-24
AU7592501A (en) 2002-07-01
CA2397990A1 (en) 2002-06-27

Similar Documents

Publication Publication Date Title
MXPA02008097A (es) Formulacion de propol con inhibicion microbiana mejorada.
ATE231003T1 (de) Tris enthaltende propofol-formulierung
CA2366793A1 (en) Propofol formulation with enhanced microbial characteristics
AU768302B2 (en) Propofol composition
EA003771B1 (ru) Композиция пропофола, включающая пентетат
WO2001052667A3 (en) Pet food composition for treating helicobacter species in pets
WO2007027819A3 (en) Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
CA2319810A1 (en) Propofol composition containing sulfite
EP1238677A3 (en) Parenteral fat emulsions comprising edetate as preservative
Özcan Inhibition of Aspergillus parasiticus NRRL 2999 by pollen and propolis extracts
Eshraghi et al. Antibacterial effects of royal jelly on different strains of bacteria
WO2004100935A3 (en) Propofol formulation containing reduced oil and surfactants
WO1999067238A3 (en) Tetrahydroquinoline-indole derivatives antimicrobial agents, their uses and compositions containing them
GB9909469D0 (en) Insectidal composition
AU2002233924A1 (en) The method of preparation and use of coconut water in mamalian tissue nourishment, growth and healthy maintenance
NZ332015A (en) Synergistic pesticidal compositions of cyprodinil and myclobutanil
WO2007000662A3 (en) Novel propofol composition comprising ascorbic acid or pharmaceutically acceptable salts thereof
DE60018567T2 (de) Verwendung von propionäure bakterien für die herstellung von propionsäure im dickdarm
AU8740198A (en) Inhibitor and preservative formulation
JP2008214206A (ja) 皮膚化粧料
Sikarwar et al. Phytochemical constituents and pharmacological activities of Lagerstroemia floribunda Jack.(Kedah bungor): A review
ATE261667T1 (de) Gallensäuren enthaltende zootechnische formulierungen
EP1180367A4 (en) DEODORANT FOR SULFIDES FROM THE COLUMN
JP2000262246A (ja) ヘリコバクターピロリの除菌剤
RU2001113082A (ru) Состав для изготовления драже

Legal Events

Date Code Title Description
FG Grant or registration